NO20075111L - Farmasoytisk sammensetning - Google Patents

Farmasoytisk sammensetning

Info

Publication number
NO20075111L
NO20075111L NO20075111A NO20075111A NO20075111L NO 20075111 L NO20075111 L NO 20075111L NO 20075111 A NO20075111 A NO 20075111A NO 20075111 A NO20075111 A NO 20075111A NO 20075111 L NO20075111 L NO 20075111L
Authority
NO
Norway
Prior art keywords
pharmaceutical composition
quinazolineamines
disordered
treatment
methods
Prior art date
Application number
NO20075111A
Other languages
English (en)
Inventor
Barry Howard Carter
Dwayne A Campbell
Original Assignee
Smithkline Beecham Cork Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37115487&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20075111(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Cork Ltd filed Critical Smithkline Beecham Cork Ltd
Publication of NO20075111L publication Critical patent/NO20075111L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

Orale farmasøytiske formuleringer inneholdende ditosylatsalter av 4-kinazolineaminer er beskrevet så vel som metoder for anvendelse av disse ved behandling av lidelseravvikende erbB familie PTK aktivitet.
NO20075111A 2005-04-19 2007-10-09 Farmasoytisk sammensetning NO20075111L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67280505P 2005-04-19 2005-04-19
PCT/US2006/014447 WO2006113649A1 (en) 2005-04-19 2006-04-18 Pharmaceutical composition

Publications (1)

Publication Number Publication Date
NO20075111L true NO20075111L (no) 2007-11-16

Family

ID=37115487

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20075111A NO20075111L (no) 2005-04-19 2007-10-09 Farmasoytisk sammensetning

Country Status (28)

Country Link
US (3) US8821927B2 (no)
EP (1) EP1871347B1 (no)
JP (1) JP5202302B2 (no)
KR (1) KR101356748B1 (no)
CN (1) CN101203211B (no)
AR (1) AR054252A1 (no)
AU (1) AU2006236423B2 (no)
BR (1) BRPI0609962B1 (no)
CA (1) CA2606207C (no)
CY (1) CY1118179T1 (no)
DK (1) DK1871347T3 (no)
EA (1) EA200702253A1 (no)
ES (1) ES2601503T3 (no)
HR (1) HRP20161429T1 (no)
HU (1) HUE030982T2 (no)
IL (1) IL186336A0 (no)
LT (1) LT1871347T (no)
MA (1) MA29404B1 (no)
MX (1) MX2007013089A (no)
NO (1) NO20075111L (no)
NZ (1) NZ562223A (no)
PE (1) PE20061430A1 (no)
PL (1) PL1871347T3 (no)
PT (1) PT1871347T (no)
SI (1) SI1871347T1 (no)
TW (1) TW200716204A (no)
WO (1) WO2006113649A1 (no)
ZA (1) ZA200708705B (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR054252A1 (es) * 2005-04-19 2007-06-13 Smithkline Beecham Cork Ltd Composicion farmaceutica oral que contiene sales de ditosilato de 4-quinazolinamina
US8252805B2 (en) 2008-05-07 2012-08-28 Teva Pharmaceutical Industries Ltd. Forms of lapatinib ditosylate and processes for preparation thereof
EP2158913A1 (en) * 2008-08-25 2010-03-03 Ratiopharm GmbH Pharmaceutical composition comprising N-[3-chhloro-4-[(3-fluorophenyl)methoxy]phenyl]6-(5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine
EP2158912A1 (en) * 2008-08-25 2010-03-03 Ratiopharm GmbH Pharmaceutical composition comprising N-[3-chhloro-4-[3-fluorophenyl)methoxy)phenyl]6-[5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine
WO2010099150A1 (en) * 2009-02-24 2010-09-02 Smithkline Beecham (Cork) Limited Pharmaceutical tablet and process
US20120245351A1 (en) * 2009-09-29 2012-09-27 Natco Pharma Limited Process for the preparation of lapatinib and its pharmaceutically acceptable salts
ES2530755T3 (es) 2010-05-21 2015-03-05 Glaxosmithkline Llc Terapia de combinación para el tratamiento del cáncer
EP2572199B1 (en) 2010-05-21 2017-03-08 Novartis AG Combination
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
WO2012018773A1 (en) 2010-08-03 2012-02-09 Altherx, Inc. Combinations of beta - 3 adrenergic receptor agonists and muscarinic receptor antagonists for treating overactive bladder
ES2635620T3 (es) 2013-02-19 2017-10-04 Hexal Ag Composición farmacéutica que comprende n-[3-cloro-4-(3-fluorobenciloxi)fenil]-6-[5({[2-(metilsulfonil)etil]amino} metil)-2-furil]quinazolin-4-amina o una sal, solvato o sal solvatada farmacéuticamente aceptables de la misma
WO2014170910A1 (en) 2013-04-04 2014-10-23 Natco Pharma Limited Process for the preparation of lapatinib
US9636340B2 (en) 2013-11-12 2017-05-02 Ayyappan K. Rajasekaran Kinase inhibitors
EA201791225A1 (ru) 2014-12-03 2017-12-29 Велисепт Терапьютикс, Инк. Композиции и способы применения солабегрона с модифицированным высвобождением при симптомах нижних мочевых путей
CN106389373B (zh) * 2015-07-29 2019-07-02 四川科伦药物研究院有限公司 一种二甲苯磺酸拉帕替尼片剂及其制备方法
CN106511289A (zh) * 2015-09-10 2017-03-22 湖北生物医药产业技术研究院有限公司 甲苯磺酸拉帕替尼片剂及其制备方法
FI3365321T3 (fi) 2015-10-23 2024-01-02 B3Ar Therapeutics Inc Solabegron-Zwitterioni ja sen käyttöjä

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506248A (en) * 1993-08-02 1996-04-09 Bristol-Myers Squibb Company Pharmaceutical compositions having good dissolution properties
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
SK146199A3 (en) 1997-04-25 2000-06-12 Janssen Pharmaceutica Nv Farnesyltransferase inhibiting quinazolinones
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
GB9800569D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
PT1294715E (pt) 2000-06-30 2007-05-31 Glaxo Group Ltd Compostos do sal de ditosilato de quinazolina
DE60203260T2 (de) 2001-01-16 2006-02-02 Glaxo Group Ltd., Greenford Pharmazeutische kombination, die ein 4-chinazolinamin und paclitaxel, carboplatin oder vinorelbin enthält, zur behandlung von krebs
JP2005534623A (ja) 2002-04-08 2005-11-17 スミスクライン ビーチャム コーポレーション Ｅｒｂファミリーの阻害剤並びにｒａｆ及び／又はｒａｓ阻害剤を投与することを含む癌の治療法
EP1810034A4 (en) 2002-06-19 2008-06-25 Smithkline Beecham Corp PREDICTIVE MARKERS IN CANCER THERAPY
AR054252A1 (es) * 2005-04-19 2007-06-13 Smithkline Beecham Cork Ltd Composicion farmaceutica oral que contiene sales de ditosilato de 4-quinazolinamina

Also Published As

Publication number Publication date
DK1871347T3 (en) 2016-11-28
PL1871347T3 (pl) 2017-04-28
EP1871347A4 (en) 2012-10-31
AU2006236423A1 (en) 2006-10-26
PE20061430A1 (es) 2007-01-25
HRP20161429T1 (hr) 2016-12-16
CN101203211A (zh) 2008-06-18
EP1871347B1 (en) 2016-08-03
MX2007013089A (es) 2008-01-14
US20080206330A1 (en) 2008-08-28
HUE030982T2 (en) 2017-06-28
US20140335177A1 (en) 2014-11-13
JP5202302B2 (ja) 2013-06-05
ES2601503T3 (es) 2017-02-15
JP2008536931A (ja) 2008-09-11
US20160143909A1 (en) 2016-05-26
AR054252A1 (es) 2007-06-13
CA2606207C (en) 2014-11-18
PT1871347T (pt) 2016-11-10
BRPI0609962B1 (pt) 2022-01-18
KR20080005557A (ko) 2008-01-14
CA2606207A1 (en) 2006-10-26
KR101356748B1 (ko) 2014-02-06
NZ562223A (en) 2010-01-29
CN101203211B (zh) 2012-08-08
MA29404B1 (fr) 2008-04-01
CY1118179T1 (el) 2017-06-28
US8821927B2 (en) 2014-09-02
BRPI0609962A2 (pt) 2011-10-11
IL186336A0 (en) 2008-01-20
LT1871347T (lt) 2016-11-10
WO2006113649A1 (en) 2006-10-26
SI1871347T1 (sl) 2016-11-30
EA200702253A1 (ru) 2008-04-28
ZA200708705B (en) 2009-12-30
AU2006236423B2 (en) 2009-12-10
EP1871347A1 (en) 2008-01-02
TW200716204A (en) 2007-05-01

Similar Documents

Publication Publication Date Title
NO20075111L (no) Farmasoytisk sammensetning
NO20170633A1 (no) Forbindelser av indolamin-2,3-dioksygenase for anvendelse i behandling av kreft i kombinasjon med et anti-PD-1 antistoff .
WO2006086562A3 (en) Phenylazetidinone derivatives
LTC1781298I2 (lt) Farmacinės kompozicijos, turinčios benzoksazino, skirtos respiracinių ligų gydymui
NO20081592L (no) Dipeptidylpeptidaseinhibitorer for behandling av diabetes
CY1112889T1 (el) Αναλογα αζετιδινης αναστολεων νουκλεοσιδασης και φωσφορυλασης
IL184898A0 (en) Pyrrolopyrimidine derivatives and pharmaceutical compositions containing the same
EA200870217A1 (ru) 4-арил-2-аминопиримидины или 4-арил-2-аминоалкилпиримидины в качестве модуляторов jak-2 и содержащие их фармацевтические композиции
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
DE602005021770D1 (de) Indol-1-yl-essigsäurederivate
TW200716628A (en) Novel compounds
EA200970273A1 (ru) Применение 2-6-(3-аминопиперидин-1-ил)-3-метил-2,4-диоксо-3,4-дигидро-2н-пиримидин-1-илметил-4-фторбензонитрила
NO20090175L (no) Stabile laquinimod sammensetninger
EA201001329A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
DK1863812T3 (da) Dipeptidylpeptidase-IV-inhiberende forbindelser, fremgangsmåder til fremstilling af de samme og farmaceutiske sammensætninger indeholdende de samme som aktive midler
NO20064078L (no) Substituerte azetidinsammensetninger, deres fremstilling og anvendelse som medikamenter
MY140514A (en) Triazolopyridine derivatives as inhibitors of lipases and phospholipases
NO20064584L (no) Tetrahydropyridoindolderivater
ECSP088763A (es) Nuevas combinaciones terapéuticas para el tratamiento de la depresión
EA201001332A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
NO20083250L (no) Antibakterielle pyrrolopyridiner, pyrrolopyrimidiner og pyrroloazepiner
EA201001330A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
TW200716091A (en) New therapeutic combinations for the treatment or prevention of psychotic disorders
ATE350377T1 (de) Substituierte 3-pyrrolidin-indol-derivate
NO341679B1 (no) Substituerte pyridylamidforbindelser, fremstilling av slike og farmasøytiske sammensetninger inneholdende slike, samt anvendelse som modulatorer av histamin H3-reseptoren

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application